CLAUDIO BLASI

Dr. CLAUDIO BLASI

Ospedale Sandro Pertini-ASLRMB
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Atherosclerosis
Verified
Journal Article
Closed access
CLAUDIO BLASICLAUDIO BLASI
CLAUDIO BLASI

1 September 1986 in Diabetes Care
Verified
Journal Article
Closed access
CLAUDIO BLASICLAUDIO BLASI
CLAUDIO BLASI
FPF. Pierelli
F. Pierelli
ERE. Rispoli
E. Rispoli
MSM. Saponara
M. Saponara
EVE. Vingolo
E. Vingolo
DAD. Andreani
D. Andreani
Four cases (belonging to two different families) of Wolfram's syndrome (WS), a rare congenital disease characterized in its complete form by insulin-dependent diabetes mellitus, optic atrophy, diabetes insipidus, deafness, and dilation of the urinary tracts are presented, and a review of the literature is included. Three of four patients are characterized by HLA-DR2 haplotype, which is rare in IDDM. The neurodegenerative nature of some symptoms and the possible pathogenesis of diabetes mellitus connected with it are discussed.


1 May 2000 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
CLAUDIO BLASICLAUDIO BLASI
CLAUDIO BLASI

12 August 2012 in Autoimmune Diseases
Verified
Journal Article
Open access
PDF file
EKEunjung Kim
Eunjung Kim
AKAnne A. Knowlton
Anne A. Knowlton
CLAUDIO BLASICLAUDIO BLASI
CLAUDIO BLASI
The diabetes-atherosclerosis relationship remains to be fully defined. Repeated prolonged hyperglycemia, increased ROS production and endothelial dysfunction are important factors. One theory is that increased blood levels of heat shock protein (HSP)60 are proinflammatory, through activation of innate immunity, and contribute to the progression of vascular disease. It was hypothesized that improvement of diabetes control in patients presenting with metabolic syndrome would lower HSP60, and anti-HSP60 antibody levels and decrease inflammatory markers. Paired sera of 17 Italian patients, before and after intensive treatment, were assayed for cytokines, HSP60 and anti-HSP60 antibodies. As expected, intensive treatment was associated with a decrease in HgbA1C (P < 0.001) and BMI (P < 0.001). After treatment, there was a significant decrease in IL-6 (P < 0.05). HSP60 levels were before treatment −6.9 + 1.9, after treatment −7.1 + 2.0 ng/mL (P = ns). Overall HSP60 concentrations were lower than published reports. Anti-HSP60 antibody titers were high and did not decrease with treatment. In conclusion, improvement of diabetic control did not alter HSP60 concentrations or antiHSP60 antibody titers, but led to a reduction of IL-6 levels.